Validation of a targeted DNA microarray for the clinical evaluation of recurrent abnormalities in chronic lymphocytic leukemia

American Journal of Hematology

Volumn 83, Issue 7, 2008, Pages 540-546

  Patel, Ankita ^a   Kang, Sung Hae ^a   Lennon, Patrick Alan ^b   Yin, Feng Li ^a   Rao, P Nagesh ^c   Abruzzo, Lynne ^b   Shaw, Chad ^a   Chinault, Alan Craig ^a   Cheung, Sau W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2;

ARTICLE; B LYMPHOCYTE; CHROMOSOME 13Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME MUTATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE LOCUS; GENE MAPPING; GENE MUTATION; GENE NUMBER; GENE TARGETING; GENETIC ASSOCIATION; GENETIC SCREENING; GENOME ANALYSIS; HUMAN; HUMAN CELL; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; GENE DOSAGE; GENOME, HUMAN; GENOMIC INSTABILITY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PILOT PROJECTS; SENSITIVITY AND SPECIFICITY;

EID: 45749089413     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21145     Document Type: Article

References (34)

1. American Cancer Society. Cancer Facts and Figures 2006. Atlanta; 2006.
2. Binet JL, Auquier A, Dighiero G, et al. A new prognostic Classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
3. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.
4. Robert KH, Moller E, Gahrton G, Eriksson H, et al. B-cell activation of peripheral blood lymphocytes from patients with chronic lymphatic leukaemia. Clin Exp Immunol 1978;33:302-308.
5. Schroder J, Vuopio P, Autio K. Chromosome changes in human chronic lymphocytic leukemia. Cancer Genet Cytogenet 1981;4:11-21.
6. Buhmann R, Kurzeder C, Rehklau J, et al. CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B-cell chronic lymphocytic leukaemia cells. Br J Haematol 2002;118: 968-975.
7. Dicker F, Schnittger S, Haferlach T et al. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006;108:3152-3160.
8. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916.
9. Matutes E, Oscier D, Garcia-Marco J, et al. Trisomy 12 defines a group of CLL with atypical morphology: Correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 1996;92:382-388.
10. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990;323:720-724.
11. Fegan C, Robinson H, Thompson P, et al. Karyotype evolution in CLL: Identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia 1995;9:2003-2008.
12. Neilson JR, Auer R, White D, et al. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia 1997;11:1929-1932.
13. Geisler CH, Philip P, Christensen BE, et al. In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most Important cytogenetic abnormalities for the prognosis: A cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. Leuk Res 1997;21:1011-1023.
14. Nowakowski GS, Dewald GW, Hoyer JD, et al. Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia. Br J Haematol 2005; 130:36-42.
15. Aoun P, Blair HE, Smith LM, et al. Fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma 2004;45:1595-1603.
16. Dyer MJ, Oscier DG. The configuration of the immuroglobulin genes in B cell chronic lymphocytic leukemia. Leukemia 2002;16:973-984.
17. Yabumoto K, Akasaka T, Muramatsu M, et al. Rearrangement of the 5′ cluster region of the BCL2 gene in lymphoid neoplasm: A summary of nine cases. Leukemia 1996;10:970-977.
18. Schwaenen C, Nessling M, Wessendorf S, et al. Automated array-based genomic profiling in chronic lymphocytic leukemia: Development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci USA 2004;101:1039-1044.
19. Ballif BC, Rorem EA, Sundin K, et al. Detection of low-level mosaicism by array CGH in routine diagnostic specimens. Am J Med Genet A 2006;140: 2757-2767.
20. Cheung SW, Shaw CA, Scott DA, et al. Microarray-based CGH detects chromosomal mosaicism not revealed by conventional cytogenetics. Am J Med Genet A 2007;143:1679-1686.
21. Garnis C, Coe BP, Lam SL, et al. High-resolution array CGH increases heterogeneity tolerance in the analysis of clinical samples. Genomics 2005;85: 790-793.
22. Dewald GW, Brockman SR, Paternoster SF, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: Correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003;121:287-295.
23. Goorha S, Glenn MJ, Drozd-Borysiuk E, Chen Z. A set of commercially available fluorescent in-situ hybridization probes efficiently detects cytogenetic abnormalities in patients with chronic lymphocytic leukemia. Genet Med 2004;6:48-53.
24. Robertson LE, Plunkett W, McConnell K, et al. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996;10:456-459.
25. Aviram A, Rabizadeh E, Zimra Y, et al. Expression of bcl-2 and bax in cells isolated from B-chronic lymphocytic leukemia patients at different stages of the disease. Eur J Haematol 2000;64:80-84.
26. Faderl S, Keating MJ, Do KA, et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002;16:1045-1052.
27. Stilgenbauer S, Bullinger L, Benner A, et al. Incidence and clinical significance of 6q deletions in B cell chronic lymphocytic leukemia. Leukemia 1999;13:1331-1334.
28. Elenitoba-Johnson KS, Gascoyne RD, Lim MS, et al. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998;91:4677-4685.
29. Schlette E, Rassidakis GZ, Canoz O, Medeiros LJ. Expression of bcl-3 in chronic lymphocytic leukemia correlates with trisomy 12 and abnormalities of chromosome 19. Am J Clin Pathol 2005;123:465-471.
30. Sellmann L, Gesk S, Walter C, et al. Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemia. Br J Haematol 2007;138:217-220.
31. Schraders M, Pfundt R, Straatman HM, et al. Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. Blood 2005;105:1686-1693.
32. Stockera KJ, Fink SR, Smoley SA, et al. Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 2006;166:152-156.
33. Glassman AB, Hayes KJ. The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia. Cancer Genet Cytogenet 2005;158:88-91.
34. Cheung SW, Shaw CA, Yu W, et al. Development and validation of a CGH microarray for clinical cytogenetic diagnosis. Genet Med 2005;7:422-432.